Results 21 to 30 of about 39,929 (263)
Haematologica, 2017 Severe graft-versus-host disease is a major barrier for non-T-cell-depleted haploidentical stem cell transplantation. There is no consensus on the optimal graft-versus-host disease prophylaxis.
Annalisa Ruggeri +17 more
doaj +1 more source
Haematologica, 2016 Improvement of graft-versus-host disease prophylaxis remains an important goal in allogeneic hematopoietic stem cell transplantation. Based on reports of possibly preferential properties of sirolimus, we compared the standard regimen of cyclosporine and ...
Johan Törlén +8 more
doaj +1 more source
Korean Journal of Transplantation, 2023 Background : Graft-versus-host disease (GVHD) is a rare, but potentially fatal complication of liver transplantation. One-way human leukocyte antigens (HLA) mismatch has emerged as a risk factor for GVHD.
Seung Hyuk Yim +4 more
doaj +1 more source
Frontiers in Immunology, 2017 BackgroundGraft-vs-host disease (GVHD) is a major complication of allogenic bone marrow transplantation (BMT). Targeting costimulatory molecules with antagonist antibodies could dampen the excessive immune response that occurs, while preserving the ...
Aude Burlion +4 more
doaj +1 more source
Prevention of graft-vs.-host disease [PDF]
Expert Opinion on Pharmacotherapy, 2012 Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment for many malignant and non-malignant hematologic disorders. However, graft-vs.-host disease (GVHD) remains a major complication of allogeneic HCT and limits the success of this approach.This paper reviews recent developments in the prevention of acute and chronic GVHD.
Andrew R, Rezvani, Rainer F, Storb
openaire +2 more sources
Treatments and supportive therapies for oral manifestations of chronic graft-versus-host disease
Acta Scientiarum. Health Sciences, 2016 The aim of this study was to conduct a systematic review of treatments and therapies for oral manifestations of chronic graft-versus-host disease, aiming at improving patients’ quality of life and mainly the reduction of mortality caused by graft-versus-
Rafaella Gabriel Maiolino +5 more
doaj +1 more source
Haematologica, 2015 Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance.
Joseph Pidala +15 more
doaj +1 more source
Hematology, Transfusion and Cell Therapy, 2018 Background: Hematopoietic stem cell transplantation is a curative treatment for many patients with hematological disorders. Donor–recipient genetic disparity, especially involving the human leukocyte antigen system is a critical factor for transplant ...
Alessandra Paz +12 more
doaj +1 more source
Frontiers in Immunology, 2020 Graft-versus-host disease (GvHD) remains the second leading cause of death in allogeneic hematopoietic stem cell transplantation recipients, highlighting the need for improved preventative strategies.
Megan S. Molina +14 more
doaj +1 more source
Frontiers in Oncology, 2021 Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances.
Justin Loke +5 more
doaj +1 more source